Listed by the USPTO as FONSECA LOPEZ, FRANCINI ALVARENGA
Tech Center 1600 • Art Units: 1635 1645 1682 1685
This examiner grants 29% of resolved cases
FONSECA LOPEZ, FRANCINI ALVARENGA has resolved 28 cases in tech center 1600 and art unit 1635. The allowance rate is 28.6%, while the median time to allowance is 1512 days. The limited record requires caution, but the observed data show a low allowance outcome and an extended prosecution timeline.
Interviews are associated with a 30.0% lift in allowance outcomes. DeepMind Technologies Limited, Thermo Fisher Scientific, and Canon Inc. are the leading companies listed. Alford Law Group, Inc., ARENTFOX SCHIFF LLP, and Barclay Damon, LLP are the leading firms shown. Applicants may benefit from early attention to claim clarity and interview preparation.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18498968 | ANALYSIS APPARATUS | Non-Final OA | Canon Kabushiki Kaisha |
| 18372565 | METHODS FOR ALLELE CALLING AND PLOIDY CALLING | Non-Final OA | Natera, Inc. |
| 17414480 | METHODS FOR IDENTIFYING NEOANTIGENS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17780037 | METHOD AND SYSTEM USING INTEGRATIVE MULTI-OMIC DATA ANALYSIS FOR EVALUATING THE FUNCTIONAL IMPACTS OF GENOMIC VARIANTS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18026058 | METHODS AND COMPOSITIONS FOR PROGNOSING GLIOBLASTOMA OR BREAST CANCER | Final Rejection | The Johns Hopkins University |
| 17806075 | TRANSFORMER-BASED GRAPH NEURAL NETWORK TRAINED WITH STRUCTURAL INFORMATION ENCODING | Non-Final OA | Microsoft Technology Licensing, LLC |
| 18443879 | EARLY DETECTION AND INTERVENTION OF AT-RISK SUBJECTS FOR PRODROMAL PARKINSON'S DISEASE | Non-Final OA | The Chinese University of Hong Kong |
| 18179144 | METHODS FOR CELL LABEL CLASSIFICATION | Non-Final OA | Becton, Dickinson And Company |
| 18182846 | RISK STRATIFICATION METHOD FOR THE DETECTION OF CANCERS IN PRECANCEROUS TISSUES | Non-Final OA | The Curators of the University of Missouri |
| 18027571 | PREDICTING SYMMETRICAL PROTEIN STRUCTURES USING SYMMETRICAL EXPANSION TRANSFORMATIONS | Non-Final OA | DeepMind Technologies Limited |
| 17849269 | DETERMINING A DISTRIBUTION OF ATOM COORDINATES OF A MACROMOLECULE FROM IMAGES USING AUTO-ENCODERS | Final Rejection | DeepMind Technologies Limited |
| 18042285 | IDENTIFYING A TARGET NUCLEIC ACID | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18224308 | METHOD AND APPARATUS FOR PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMEN | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18279526 | NATURAL LANGUAGE PROCESSING TO PREDICT PROPERTIES OF PROTEINS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 17571774 | Diagnosis of Antibiotic Resistance Genes in Clinical Specimens | Final Rejection | AOS Bioinnovations, LLC |
| 17563103 | AI SIMULATION FOR MICROALGAE FERMENTATION | Final Rejection | Sophie's BioNutrients Pte. Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy28.6% of resolved applications examined by Francini Alvarenga Fonseca Lopez were allowed (28 resolved cases), compared with 51.6% across Art Unit 1635 over the last five years.
This examiner's interview lift is +30.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Francini Alvarenga Fonseca Lopez took 1,512 days on average from filing to allowance.
Francini Alvarenga Fonseca Lopez examines applications in Art Unit 1635 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
